HHT Research Breakthroughs

November 11, 2015
Presented by: Dr. Christopher Hughes, Chair, Cure HHT Global Research and Medical Advisory Board and Dr. James Gossage, Cure HHT Medical Director


Dr. Christopher Hughes is a Professor at the University of California at Irvine and Chair of Cure HHT’s Global Research and Medical Advisory Board. Dr. Hughes holds a Bachelor’s of Science (Hon) degree from University College, London, England and a PhD from King’s College, University of London focusing in neuropathology. Dr. Hughes has extensive experience in the field of vascular biology and the process of angiogenesis, in particular, his lab has studied the role of notch signaling in vascular development and they were the first to demonstrate the role of notch in regulating tip cell function during angiogenic sprouting.

Dr. James Gossage is Director of the Pulmonary Vascular Disease program and HHT program at Georgia Regents University and he is the Medical Director for Cure HHT. He received his medical degree in 1984 and did a fellowship in Pulmonary and Critical Care Medicine at Vanderbilt University from 1988-1991. Dr. Gossage has taken care of HHT patients since 1995 and opened up his HHT Center of Excellence in 2003. In 2008 he was appointed Medical Director of the HHT Foundation, now known as Cure HHT. Dr. Gossage’s research and clinical interests include HHT, pulmonary hypertension, pulmonary embolism, and right heart catheterization.


The 11th International HHT Scientific Conference, sponsored primarily by Cure HHT, brought together 250 of the world’s leading HHT experts in both basic research as well as clinical practice focusing on translation of findings between the fields. Basic research is the engine that drives discovery of new drugs and therapies, but it relies on constant input and feedback from clinicians.

Join Drs. Hughes and Gossage as they review advances in HHT research and treatment presented at the 2015 International HHT Scientific Conference. Hear about advancements in Avastin treatment for bleeding; screening and treatments for PAVMs; and the latest basic science research that will lead to clinical trials and drug therapy! After the presentation, they answered your most pressing questions.

Webinar Highlights

  • Executive Summary of the research presented at the 11th International HHT Scientific Conference; published in the October 2015 edition of Angiogenesis This publication is free to view from now through December 15, 2015.
  • Download the pdf of the Executive Summary and the Abstracts presented at the 11th International Scientific Conference as they were published in the October 2015 edition of Angiogenesis
  • Novel drug therapy effectiveness reported in clinical trials
  • Valuable information collected through Outcomes Registry in France
  • New protocols for follow-up screenings of lung AVMs in HHT patients

Cure HHT

Cure HHT is the cornerstone of the HHT community, advancing one common hope - to give those affected by HHT a chance for a normal life. This webinar series is just one of many ways we accomplish this mission. If you found value in this information, please consider making a donation NOW to keep this initiative moving forward. It is through the generosity of our donors that we can continue to provide this valuable education to the HHT community.

 Donate Now Button - Blue Rectangle

 (Please write "webinar" in comment section of donation form)